{"id":"NCT00938392","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07-30","primaryCompletion":"2009-10-05","completion":"2009-10-05","firstPosted":"2009-07-13","resultsPosted":"2012-05-17","lastUpdate":"2018-08-20"},"enrollment":726,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational FluNG vaccine GSK2186877A, aged lot","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK investigational FluNG vaccine GSK2186877A, fresh lot","otherNames":[]}],"arms":[{"label":"FluNG Aged Group","type":"EXPERIMENTAL"},{"label":"FluNG Fresh Group","type":"EXPERIMENTAL"}],"summary":"The objective of the study is to evaluate immunogenicity between different formulations of GSK Biologicals' investigational vaccine GSK2186877A.","primaryOutcome":{"measure":"Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains","timeFrame":"At Days 0 and 21","effectByArm":[{"arm":"FluNG Aged Group","deltaMin":14.1,"sd":null},{"arm":"FluNG Fresh Group","deltaMin":13.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":6,"countries":["Estonia","Slovakia"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":362},"commonTop":["Pain at the injection site","Redness at the injection site","Fatigue","Headache","Muscle aches"]}}